Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

Area of Science:

• Pharmacology
• Oncology
• Cardiology

Background:

• Angiosarcoma treatment options are limited.
• Beta-blockers are being investigated as a novel therapeutic strategy for angiosarcoma.
• Most angiosarcoma patients lack cardiovascular comorbidities, necessitating careful drug selection.

Purpose of the Study:

• To determine the optimal pharmacological properties of beta-blockers for angiosarcoma treatment.
• To identify beta-blockers that maximize efficacy while minimizing cardiovascular adverse events in angiosarcoma patients.

Main Methods:

• Review of in vitro data regarding beta-blocker effectiveness in angiosarcoma.
• Analysis of pharmacological properties, including intrinsic sympathomimetic activity and vasodilator effects.
• Examination of existing clinical data on beta-blocker use in angiosarcoma.

Main Results:

• Non-selective beta-blockers are preferred for maximizing potential effectiveness in angiosarcoma based on in vitro data.
• Beta-blockers with intrinsic sympathomimetic activity or vasodilator effects (e.g., labetalol, pindolol, carvedilol) are suggested to minimize cardiovascular risks.
• Currently, only propranolol has available efficacy data, with one reported case of carvedilol use.

Conclusions:

• Non-selective beta-blockers are a promising avenue for angiosarcoma therapy.
• Labetalol, pindolol, or carvedilol are potential candidates for future studies to mitigate cardiovascular adverse events.
• Further research is needed to evaluate the efficacy and safety of specific beta-blockers in angiosarcoma patients without cardiovascular comorbidities.